Log In
BCIQ
Print this Print this
 

Emend, Ivemend, Proemend, fosaprepitant dimeglumine, fosaprepitant meglumine (MK-0517, ONO-7847)

Also known as: Emend For Injection

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionInjectable formulation of the selective tachykinin receptor (TACR1; NK1R) receptor antagonist
Molecular Target Tachykinin receptor (TACR1) (NK1R)
Mechanism of ActionTachykinin receptor (TACR1) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients ages 6 months-17 years; Treat digestive symptoms resulting from the administration of antineoplastic agents.
Regulatory Designation
PartnerOno Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today